Cambridge, UK-based cell therapy specialist Intercytex has closed the 396-patient enrollment for its Phase III study of Cyzact (formerly known as ICX-PRO).
The trial is a controlled, double-blind study for the drug as therapy for venous leg ulcers. It believed to be the first study of a cell therapy for the treatment of chronic wounds. Cyzact is a topical woundcare product designed to stimulate active healing and closure in persistent chronic wounds.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze